Biota Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

BOTA 2.41 +0.08 (3.43%)
price chart
What after Joseph Patti's Insider Purchase of Biota Pharmaceuticals Inc ...
Joseph Patti; that is an insider in Biota Pharmaceuticals Inc (NASDAQ:BOTA) who is the latest to obtain shares in the firm for which he is the current CEO.
Insider Buying: Joseph M. Patti Purchases 20000 Shares of Biota ...  The Legacy
Biota Pharmaceuticals CEO Joseph M. Patti Purchases 20000 Shares (BOTA)  WKRB News
Biota Pharmaceuticals Inc Stock Downgraded (BOTA)
The gross profit margin for BIOTA PHARMACEUTICALS INC is currently lower than what is desirable, coming in at 34.92%. It has decreased significantly from the same period last year.
Related articles »  
Biota Pharmaceuticals: Recent Progress Illustrates Buying Opportunity Remains ...
While the termination of the BARDA contract in April 2014 that provided up $231 million for the development of laninamivir octanoate had a substantial negative effect on Biota in 2014 as it took away a source of major funding, the company has made ...
Biota Pharmaceuticals (BOTA) Upgraded From Sell to Hold
"We rate BIOTA PHARMACEUTICALS INC (BOTA) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative ...
Massive Swings: Biota Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.
Healthcare investors were presented with major movements in two small stocks today: Amicus Therapeutics (NASDAQ: FOLD ) popped almost 21% on strong phase 3 data for a Fabry disease drug, while Biota Pharmaceuticals (NASDAQ: BOTA ) collapsed ...
Related articles »  
Biota Pharmaceuticals Inc. And Venaxis Inc.: 2 Upcoming Biopharmaceuticals ...
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) is a biopharmaceutical company focused on the discovery and development of anti-infective products to prevent and treat a number of serious and potentially life-threatening infectious diseases.
Biota Pharmaceuticals: An Undervalued Long-Term Influenza Play (BOTA)
There is also $3.7 million of deferred revenue that Biota has not included as accrued revenue as the company is less certain of its collection.
Biota Pharmaceuticals to Acquire Anaconda Pharma
ATLANTA, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals (Nasdaq:BOTA) (the "Company") announced today that it has entered into a definitive agreement to acquire Anaconda Pharma, a privately-held biotechnology company based in Paris, ...
Biota to Acquire Anaconda Pharma for Up-to-$38M  Genetic Engineering & Biotechnology News
Biota Pharmaceuticals' (BOTA) CEO Joseph Patti on F2Q 2015 Results ...
Biota Pharmaceuticals' (BOTA) CEO Joseph Patti on Q2 2015 Results - Earnings Call Transcript. | Feb. 5, 2015 11:25 AM ET | About: Biota Pharmaceuticals, Inc. (BOTA) by: SA Transcripts. Biota Pharmaceuticals, Inc. (NASDAQ:BOTA). Q2 2015 Results ...
Biota Pharmaceuticals Reports Second Quarter Fiscal Year 2015 Financial Results  Nasdaq
Biota Pharmaceuticals Inc (BOTA): Biota Pharma's Game-Changer, Laninamivir ...
Biota Pharmaceuticals (NASDAQ:BOTA) was originally an Australian company developing anti-viral medications. Subsequently it has moved to the NASDAQ, raising $27m through its reverse takeover of Nabi Pharmaceuticals. Biota currently has two products ...